8:00 am Registration & Breakfast

8:50 am Chair’s Opening Remarks

Targeting Solid & Hard to Treat Liquid Tumors: Designing the Next Generation of Cell Engagers

9:00 am Enhancing the Therapeutic Window with a Novel Conditional Bispecific T Cell Engager for Successful Application in Solid Tumors

  • Antara Banerjee Director, Head Cell Engager Therapies, Oncology Drug Discovery Unit, Takeda Pharmaceutical Co. Ltd.

Synopsis

  • Highlight challenges and expose key bottlenecks
  • Analyze structural arrangement of the VH and VL Domains in the COBRATM
  • Explore domain rearrangement and widening the therapeutic index using a novel conditionally activated FIC T cell engager for solid tumors

9:30 am Triclonics™ ENGAGE: Trispecific Antibody Platform for Tumor Specific T-Cell Engagers

Synopsis

  • Identify targets for Triclonics antibodies
  • Explore therapeutic opportunities of trispecific T-cell engagers
  • Overcome T-cell engager toxicities

10:00 am Non-Genetic Chemoenzymatic Modification of Antibody Glycans (GlycoConnect™): from ADCs to Immune Cell Engagers with Tailored Architecture

Synopsis

  • Non-genetic attachment of scFv (anti-CD3) or cytokine (IL-15) to antibody glycan based on clinical stage GlycoConnect™ technology
  • Molecular architecture of readily tailored to 2:2 or 2:1 (bispecifics) or 2:1:1 (trispecifics)
  • Functional in vitro and in vivo studies corroborate the biological activity of GlycoConnect™ immune cell engagers

10:15 am Targeting Alternative T Cell Effector Pathways To Enhance The Anti-Tumor Activity Of CD3-Engaging Bispecific Antibodies

  • David DiLillo Director, Immuno-Oncology, Regeneron Pharmaceuticals Inc.

Synopsis

  • Assess how CD3-engaging bispecific antibodies drive potent anti-tumor activity in pre-clinical models as well as in patients
  • Consider how not all patients respond to therapy, and many relapse after initially responding
  • Describe novel reagents that engage alternative T cell signaling pathways and demonstrate combinatorial anti-tumor effects in high-bar pre-clinical models

10:45 am
Morning Refreshments & Speed Networking Break

11:45 am AMG 509, A STEAP1-Targeted Bispecific Immune Therapy for the Treatment of Prostate Cancer & Ewing Sarcoma

Synopsis

  • Discuss Novel STEAP1 x CD3 T cell-recruiting XmAb® 2+1 bispecific antibody
  • Learn how AMG 509 demonstrates potent and selective T cell-mediated killing of STEAP1+ cancer cell lines in vitro and in vivo
  • Examine promising preclinical data supporting ongoing evaluation of AMG 509 in a phase 1, first-in-human study in patients with metastatic castration-resistant prostate cancer

12:15 pm Panel Discussion & Roundtable: Achieving Success as a Field – How Can Cell Engagers Stand Out in a Competitive Landscape?

  • Joachim Koch Senior Director, Head Translational Research & Innovation, Affimed GmbH
  • Antara Banerjee Director, Head Cell Engager Therapies, Oncology Drug Discovery Unit, Takeda Pharmaceutical Co. Ltd.
  • Jessica Kirshner Senior Director, Oncology & Angiogenesis , Regeneron Pharmaceuticals Inc.

Synopsis

The Cell Engager Summit is in it’s 4th year – it is therefore key that drug developers take note of the field’s progress and the hurdles that still lie ahead. Here we will ask:

  • What are the current challenges of the field?
  • Which key parameters can be used to determine what is truly working within the space? I.e., for some, cellular products’ persistence is often highlighted. What about the cellular transfers and persistence of the cell product?
  • What are the key drivers pushing this space forward?

1:00 pm
Lunch Break

2:00 pm A Tale of Two T Cell Engagers: Selecting the Optimal Target, Design, & Patient Population

  • Kristan Meetze Vice President, Preclinical & Early Development, Cullinan Oncology

Synopsis

  • Understand how format, affinity, and valency of T-cell engagers must be carefully selected based on target expression profiles in the intended patient population
  • Hear about CLN-049, a clinical stage FLT3xCD3 IgG-based bispecific antibody targeting AML blasts across a wide range of FLT3 expression levels, which spares normal cells that express low levels of FLT3
  • Discuss CLN-978, a preclinical stage half-life extended CD19xCD3 fusion protein with a very high affinity for CD19, which enables redirected lysis of B-cell malignant blasts with reduced CD19 expression levels

2:30 pm Presentation from our Spotlight Partner Aracari Biosciences

Selecting Appropriate Targets to Pursue

2:40 pm Mechanistic & Pharmacodynamic Studies of Duobody-CD3x5T4 In Preclinical In Vitro & In Vivo Models

Synopsis

  • Discuss DuoBody®-CD3x5T4, an Fc-silenced CD3 bsAb that crosslinks CD3 on T cells with 5T4 on tumor cells
  • Hear how T-cell mediated cytotoxicity was induced by DuoBody-CD3x5T4 in 5T4+ tumor cells, associated with T-cell activation, proliferation and cytokine production in vitro
  • Learn how DuoBody-CD3x5T4 has shown preclinical anti-tumor activity in multiple solid cancer CDX/PDX models in humanized mice, which was associated with T-cell activation in the tumor and periphery

Afternoon Coffee Break

4:00 pm CD20xCD3 IgM Bispecific Antibody IGM-2323 Induces T-Cell Dependent & Complement Dependent Cytotoxicity with Minimal Cytokine Release

Synopsis

  • As we know, current bispecific antibodies are largely based on IgG-like scaffolds and though some success has been seen in the clinic, adverse events related to cytokine release remain a major concern
  • Hear about IGM-2323, an engineered IgM bispecific antibody that uses an anti-CD20 IgM to provide high avidity binding to CD20, a scFv fused to the N-terminus of J-chain to provide monovalent engagement of CD3 on T-cells, and human serum albumin (HSA) fused to the C-terminus of J-chain to improve pharmacokinetics
  • View IGM Bio’s preclinical data, demonstrating IGM-2323 is highly effective at complement dependent cytotoxicity and T-cell dependent cellular cytotoxicity killing of tumor cells with minimal cytokine release and is currently in a Phase II clinical trial in Non-Hodgkin’s Lymphoma

4:30 pm Challenging the Predictability of Pre-Clinical Models for Assessment of T Cell Engagers

  • Kader Thiam Senior Vice President - Discovery – Preclinical Models & Services, Genoway

Synopsis

  • Focus on BRGSF-HIS hCD34+ reconstituted mice featuring human lymphoid and myeloid compartments and syngeneic humanized mouse models:
  • Characterization of the immune response in the mice
  • Assessment of efficacy and irAE induced by T cell engagers
  • Pros and cons of these models

5:00 pm Closing Remarks & End of Day One